Research programme: central nervous system therapeutics - Inhibikase Therapeutics

Drug Profile

Research programme: central nervous system therapeutics - Inhibikase Therapeutics

Alternative Names: Dasatnib - Inhibikase Therapeutics; IkT-01427; IkT-01427/IkT-148009; IkT-148009; Nilotinib - Inhibikase Therapeutics

Latest Information Update: 27 Sep 2016

Price : $50

At a glance

  • Originator Inhibikase Therapeutics
  • Class Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease; Progressive multifocal leukoencephalopathy

Most Recent Events

  • 21 Sep 2016 Preclinical trials in Parkinson's disease in USA (PO)
  • 21 Sep 2016 Preclinical trials in Progressive multifocal leukoencephalopathy in USA (unspecified route)
  • 14 Sep 2016 Inhibikase Therapeutics announces intention to submit IND to the US FDA in first quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top